Holen Sie sich die Stockscreener-App
22.58
4.12%
-0.97
Schlusskurs vom Vortag:
$23.55
Offen:
$23.21
24-Stunden-Volumen:
3.00M
Relative Volume:
1.08
Marktkapitalisierung:
$3.21B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-412.89M
KGV:
-5.8497
EPS:
-3.86
Netto-Cashflow:
$-361.93M
1W Leistung:
+31.89%
1M Leistung:
+78.50%
6M Leistung:
+91.52%
1J Leistung:
-21.76%
1-Tages-Spanne:
$22.23
$23.34
1-Wochen-Bereich:
$22.23
$25.00
52-Wochen-Spanne:
$6.36
$35.68
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Vergleichen Sie DYN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
22.58 | 3.35B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | -52.09M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Historical volatility pattern of Dyne Therapeutics Inc. visualizedJuly 2025 PreEarnings & Intraday High Probability Alerts - newser.com
Sector ETF performance correlation with Dyne Therapeutics Inc.2025 Price Momentum & Smart Money Movement Tracker - newser.com
Can trapped investors hope for a rebound in Dyne Therapeutics Inc.July 2025 Opening Moves & Fast Moving Trade Plans - newser.com
Analyzing Dyne Therapeutics Inc. with risk reward ratio charts2025 Trading Volume Trends & Accurate Trade Setup Notifications - newser.com
Dyne Therapeutics Inc.’s volatility index tracking explainedRate Hike & Low Drawdown Investment Strategies - newser.com
Is Dyne Therapeutics Inc. stock entering bullish territory2025 Top Gainers & Reliable Volume Spike Alerts - newser.com
Technical analysis overview for Dyne Therapeutics Inc. stock2025 Technical Patterns & Low Drawdown Investment Ideas - newser.com
Using RSI to spot recovery in Dyne Therapeutics Inc.2025 Winners & Losers & Technical Entry and Exit Tips - newser.com
Is Dyne Therapeutics Inc. reversing from oversold territoryPortfolio Value Summary & Fast Exit and Entry Strategy Plans - newser.com
Is Dyne Therapeutics Inc. stock gaining market share2025 Investor Takeaways & Stock Portfolio Risk Management - newser.com
What recovery options are there for Dyne Therapeutics Inc.Market Risk Analysis & Low Volatility Stock Suggestions - newser.com
Why Dyne Therapeutics Inc. stock is seen as undervaluedGDP Growth & Stock Portfolio Risk Control - newser.com
Will Dyne Therapeutics Inc. stock deliver better than expected guidance2025 Dividend Review & Safe Capital Investment Plans - newser.com
How moving averages guide Dyne Therapeutics Inc. trading2025 Year in Review & Stock Timing and Entry Methods - newser.com
Is Dyne Therapeutics Inc. stock a bargain at current levels2025 Geopolitical Influence & Reliable Breakout Stock Forecasts - newser.com
Qualcomm, Tesla, Intellia Therapeutics, Avidity Biosciences, Dyne Therapeutics: Stocks Making The Biggest Moves Today - MSN
Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis - MSN
Can you recover from losses in Dyne Therapeutics Inc.Recession Risk & AI Forecast Swing Trade Picks - newser.com
Dyne Therapeutics (NASDAQ:DYN) Shares Gap UpStill a Buy? - MarketBeat
10 Big Names Crushing Wall Street - Insider Monkey
Dyne (DYN) Jumps 41% as Jefferies Bets Firm to Benefit from Novartis-Avidity Merger - Insider Monkey
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dyne Therapeutics Inc-Aktie (DYN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Friedl-Naderer Johanna | Chief Commercial Officer |
Sep 04 '25 |
Sale |
13.27 |
894 |
11,863 |
95,017 |
| Friedl-Naderer Johanna | Chief Commercial Officer |
Sep 05 '25 |
Sale |
13.41 |
144 |
1,931 |
94,873 |
| Kerr Douglas | Chief Medical Officer |
Sep 04 '25 |
Sale |
13.27 |
3,552 |
47,135 |
89,263 |
| Kerr Douglas | Chief Medical Officer |
Sep 05 '25 |
Sale |
13.41 |
873 |
11,707 |
88,390 |
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):